Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Steven Gabardi, Pharm.D.

Title
Institution
Department
Address
Phone
Fax
Profile Picture

Biography
awards and honors
2006
Academic-Practice Partnership Initiative
2011
Practitioners Excellence Award
2011
Fellowship
2011
Pharmacy Preceptor of the Year

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Rimsans J, Sylvester K, Kim M, Connors JM, Gabardi S. A Review of Direct-acting Oral Anticoagulants and Their Use in Solid Organ Transplantation. Transplantation. 2022 11 01; 106(11):2143-2154. PMID: 35642975.
    Citations:    Fields:    
  2. Gabardi S. Immunosuppression in the Age of Precision Medicine. Semin Nephrol. 2022 01; 42(1):86-98. PMID: 35618398.
    Citations:    Fields:    Translation:Humans
  3. Rogers R, Bodziak K, Cheema F, Chobanian M, Ebcioglu Z, Gabardi S, Ghai S, Gilligan H, Gohh R, Goyal N, Kavalam G, Mehri B, Rodig N, Rossi A, Singh J, Wood E, Tan CS, Pavlakis M. Implementing a regional standardized BK polyomavirus screening protocol across eleven transplant centres. Transpl Int. 2021 12; 34(12):2680-2685. PMID: 34628685.
    Citations:    Fields:    Translation:HumansCells
  4. Gabardi S. Unraveling the Genomic Architecture of the CYP3A Locus and ADME Genes for Personalized Tacrolimus Dosing. Transplantation. 2021 10 01; 105(10):2135-2136. PMID: 33534527.
    Citations:    Fields:    
  5. Rizk JG, Lazo JG, Quan D, Gabardi S, Rizk Y, Streja E, Kovesdy CP, Kalantar-Zadeh K. Mechanisms and management of drug-induced hyperkalemia in kidney transplant patients. Rev Endocr Metab Disord. 2021 12; 22(4):1157-1170. PMID: 34292479.
    Citations:    Fields:    Translation:Humans
  6. Rizk J, Quan D, Gabardi S, Rizk Y, Kalantar-Zadeh K. Novel approaches to management of hyperkalaemia in kidney transplantation. Curr Opin Nephrol Hypertens. 2021 01; 30(1):27-37. PMID: 33027094.
    Citations: 4     Fields:    Translation:Humans
  7. Zimmerman A, Rogers R, Tan CS, Pavlakis M, Bodziak K, Cardarelli F, Francis J, Gabardi S, Germain M, Ghai S, Gilligan H, Goyal N, Malinis M, Patel H, Rodig N, Theodoropoulos NM, Walshe E, Wood E, Chobanian M. Expecting the unexpected: COVID-19 in Kidney Transplant Recipients within United Network for Organ Sharing Region 1. Transpl Int. 2020 12; 33(12):1843-1844. PMID: 33000866; PMCID: PMC7536934.
    Citations: 1     Fields:    Translation:Humans
  8. Tan CS, Gabardi S, Pavlakis M. Survey of BK virus screening practices by American society of transplantation members. Clin Transplant. 2019 07; 33(7):e13620. PMID: 31152561.
    Citations:    Fields:    Translation:HumansCellsPHPublic Health
  9. Pérez-Sáez MJ, Yu B, Uffing A, Murakami N, Borges TJ, Azzi J, El Haji S, Gabardi S, Riella LV. Conversion from tacrolimus to belatacept improves renal function in kidney transplant patients with chronic vascular lesions in allograft biopsy. Clin Kidney J. 2019 Aug; 12(4):586-591. PMID: 31384452; PMCID: PMC6671390.
    Citations: 1     
  10. Gabardi S, Pavlakis M, Tan C, Francis J, Cardarelli F, Asch W, Bodziak K, Chobanian M, Gilligan H, Gohh R, Kung SC, Inker L, Martin S, Rodig N, Rossi A, Chandraker A. New England BK consortium: Regional survey of BK screening and management protocols in comparison to published consensus guidelines. Transpl Infect Dis. 2018 Dec; 20(6):e12985. PMID: 30175491.
    Citations:    Fields:    Translation:HumansCells
  11. Alsheikh R, Gabardi S. Post-Renal Transplantation Outcomes in Elderly Patients Compared to Younger Patients in the Setting of Early Steroid Withdrawal. Prog Transplant. 2018 12; 28(4):322-329. PMID: 30213228.
    Citations: 3     Fields:    Translation:Humans
  12. Kim M, Bergmark BA, Zelniker TA, Mehra MR, Stewart GC, Page DS, Woodcome EL, Smallwood JA, Gabardi S, Givertz MM. Early aspirin use and the development of cardiac allograft vasculopathy. J Heart Lung Transplant. 2017 Dec; 36(12):1344-1349. PMID: 28781013.
    Citations: 4     Fields:    Translation:Humans
  13. Gabardi S, van Gelder T. Causes and Consequences of the Worldwide Belatacept Shortage. Transplantation. 2017 07; 101(7):1520-1521. PMID: 28376033.
    Citations: 3     Fields:    
  14. Mallat SG, Tanios BY, Itani HS, Lotfi T, McMullan C, Gabardi S, Akl EA, Azzi JR. CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials. Clin J Am Soc Nephrol. 2017 Aug 07; 12(8):1321-1336. PMID: 28576905; PMCID: PMC5544521.
    Citations: 26     Fields:    Translation:HumansCells
  15. Yeung MY, Gabardi S, Sayegh MH. Use of polyclonal/monoclonal antibody therapies in transplantation. Expert Opin Biol Ther. 2017 03; 17(3):339-352. PMID: 28092486.
    Citations: 4     Fields:    Translation:HumansAnimals
  16. Krenzien F, Quante M, Heinbokel T, Seyda M, Minami K, Uehara H, Biefer HRC, Schuitenmaker JM, Gabardi S, Splith K, Schmelzle M, Petrides AK, Azuma H, Pratschke J, Li XC, ElKhal A, Tullius SG. Age-Dependent Metabolic and Immunosuppressive Effects of Tacrolimus. Am J Transplant. 2017 May; 17(5):1242-1254. PMID: 27754593; PMCID: PMC5395364.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  17. Heldenbrand S, Li C, Cross RP, DePiero KA, Dick TB, Ferguson K, Kim M, Newkirk E, Park JM, Sudaria-Kerr J, Tichy EM, Ueda KR, Weng R, Wisniewski J, Gabardi S. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients. Transpl Infect Dis. 2016 Dec; 18(6):904-912. PMID: 27639246.
    Citations: 4     Fields:    Translation:HumansCells
  18. Gabardi S, Martin S, Sura M, Mohammed A, Golan Y. Micafungin treatment and eradication of candiduria among hospitalized patients. Int Urol Nephrol. 2016 Nov; 48(11):1881-1885. PMID: 27587066.
    Citations: 6     Fields:    Translation:HumansAnimals
  19. Lin MV, Sise ME, Pavlakis M, Amundsen BM, Chute D, Rutherford AE, Chung RT, Curry MP, Hanifi JM, Gabardi S, Chandraker A, Heher EC, Elias N, Riella LV. Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection. PLoS One. 2016; 11(7):e0158431. PMID: 27415632.
    Citations: 32     Fields:    Translation:Humans
  20. Phillips K, Reddy P, Gabardi S. Is There Evidence to Support Brand to Generic Interchange of the Mycophenolic Acid Products? J Pharm Pract. 2017 Feb; 30(1):9-16. PMID: 26043743.
    Citations: 3     Fields:    Translation:Humans
  21. Riella LV, Gabardi S, Azzi J. Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med. 2016 06 30; 374(26):2599-600. PMID: 27355545.
    Citations: 1     Fields:    Translation:Humans
  22. Nauffal M, Gabardi S. Nephrotoxicity of Natural Products. Blood Purif. 2016; 41(1-3):123-9. PMID: 26766569.
    Citations: 4     Fields:    Translation:Humans
  23. Krenzien F, ElKhal A, Quante M, Rodriguez Cetina Biefer H, Hirofumi U, Gabardi S, Tullius SG. A Rationale for Age-Adapted Immunosuppression in Organ Transplantation. Transplantation. 2015 Nov; 99(11):2258-68. PMID: 26244716; PMCID: PMC4618718.
    Citations: 31     Fields:    Translation:HumansAnimals
  24. Gabardi S, Tullius SG, Krenzien F. Understanding alterations in drug handling with aging: a focus on the pharmacokinetics of maintenance immunosuppressants in the elderly. Curr Opin Organ Transplant. 2015 Aug; 20(4):424-30. PMID: 26126198.
    Citations: 3     Fields:    Translation:Humans
  25. Gabardi S, Asipenko N, Fleming J, Lor K, McDevitt-Potter L, Mohammed A, Rogers C, Tichy EM, Weng R, Lee RA. Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients. Transplantation. 2015 Jul; 99(7):1499-505. PMID: 25643140.
    Citations: 3     Fields:    Translation:Humans
  26. Gabardi S, Ramasamy S, Kim M, Klasek R, Carter D, Mackenzie MR, Chandraker A, Tan CS. Impact of HMG-CoA reductase inhibitors on the incidence of polyomavirus-associated nephropathy in renal transplant recipients with human BK polyomavirus viremia. Transpl Infect Dis. 2015 Aug; 17(4):536-43. PMID: 25989423.
    Citations: 3     Fields:    Translation:HumansCells
  27. Maldonado AQ, Tichy EM, Rogers CC, Campara M, Ensor C, Doligalski CT, Gabardi S, Descourouez JL, Doyle IC, Trofe-Clark J. Assessing pharmacologic and nonpharmacologic risks in candidates for kidney transplantation. Am J Health Syst Pharm. 2015 May 15; 72(10):781-93. PMID: 25941253.
    Citations: 1     Fields:    Translation:Humans
  28. El Hajj S, Kim M, Phillips K, Gabardi S. Generic immunosuppression in transplantation: current evidence and controversial issues. Expert Rev Clin Immunol. 2015 May; 11(5):659-72. PMID: 25817258.
    Citations: 3     Fields:    Translation:HumansAnimals
  29. Safa K, Logan MS, Batal I, Gabardi S, Rennke HG, Abdi R. Eculizumab for drug-induced de novo posttransplantation thrombotic microangiopathy: A case report. Clin Nephrol. 2015 Feb; 83(2):125-9. PMID: 24495904.
    Citations: 10     Fields:    Translation:Humans
  30. Riella LV, Safa K, Yagan J, Lee B, Azzi J, Najafian N, Abdi R, Milford E, Mah H, Gabardi S, Malek S, Tullius SG, Magee C, Chandraker A. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch. Transplantation. 2014 Jun 27; 97(12):1247-52. PMID: 24854670.
    Citations: 13     Fields:    Translation:Humans
  31. Kim M, Townsend KR, Wood IG, Boukedes S, Guleria I, Gabardi S, El-Chemaly S, Camp PC, Chandraker AK, Milford EL, Goldberg HJ. Impact of pretransplant anti-HLA antibodies on outcomes in lung transplant candidates. Am J Respir Crit Care Med. 2014 May 15; 189(10):1234-9. PMID: 24749479.
    Citations: 20     Fields:    Translation:Humans
  32. Kim M, Martin ST, Townsend KR, Gabardi S. Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options. Pharmacotherapy. 2014 Jul; 34(7):733-44. PMID: 24753207.
    Citations: 18     Fields:    Translation:HumansAnimals
  33. Martin ST, Cardwell SM, Nailor MD, Gabardi S. Hepatitis B reactivation and rituximab: a new boxed warning and considerations for solid organ transplantation. Am J Transplant. 2014 Apr; 14(4):788-96. PMID: 24592928.
    Citations: 14     Fields:    Translation:HumansCells
  34. Rostas S, Kim M, Gabardi S. Risk evaluation and mitigation strategies: a focus on the mycophenolic acid preparations. Prog Transplant. 2014 Mar; 24(1):33-6. PMID: 24598563.
    Citations: 1     Fields:    Translation:Humans
  35. Lee BT, Gabardi S, Grafals M, Hofmann RM, Akalin E, Aljanabi A, Mandelbrot DA, Adey DB, Heher E, Fan PY, Conte S, Dyer-Ward C, Chandraker A. Efficacy of levofloxacin in the treatment of BK viremia: a multicenter, double-blinded, randomized, placebo-controlled trial. Clin J Am Soc Nephrol. 2014 Mar; 9(3):583-9. PMID: 24482066.
    Citations: 22     Fields:    Translation:HumansCells
  36. Aitken SL, Palmer HR, Topal JE, Gabardi S, Tichy E. Call for antimicrobial stewardship in solid organ transplantation. Am J Transplant. 2013 Sep; 13(9):2499. PMID: 23865747.
    Citations: 6     Fields:    Translation:Humans
  37. Gabardi S, Townsend K, Martin ST, Chandraker A. Evaluating the impact of pre-transplant desensitization utilizing a plasmapheresis and low-dose intravenous immunoglobulin protocol on BK viremia in renal transplant recipients. Transpl Infect Dis. 2013 Aug; 15(4):361-8. PMID: 23647907.
    Citations: 6     Fields:    Translation:HumansCells
  38. Kim M, Rostas S, Gabardi S. Mycophenolate fetal toxicity and risk evaluation and mitigation strategies. Am J Transplant. 2013 Jun; 13(6):1383-9. PMID: 23617812.
    Citations: 19     Fields:    Translation:Humans
  39. Gabardi S, Tichy EM. A guide to understanding and implementing risk evaluation and mitigation strategies in organ transplantation. Prog Transplant. 2013 Mar; 23(1):58-62; quiz 63. PMID: 23448822.
    Citations: 2     Fields:    Translation:Humans
  40. Sam T, Gabardi S, Tichy EM. Risk evaluation and mitigation strategies: a focus on belatacept. Prog Transplant. 2013 Mar; 23(1):64-70. PMID: 23448823.
    Citations: 2     Fields:    Translation:Humans
  41. Gabardi S. Risk evaluation and mitigation strategies: a focus on the mammalian target of rapamycin inhibitors. Prog Transplant. 2013 Mar; 23(1):55-7. PMID: 23448821.
    Citations:    Fields:    Translation:Humans
  42. van Gelder T, Gabardi S. Methods, strengths, weaknesses, and limitations of bioequivalence tests with special regard to immunosuppressive drugs. Transpl Int. 2013 Aug; 26(8):771-7. PMID: 23441971.
    Citations: 3     Fields:    Translation:Humans
  43. Hammond SP, Martin ST, Roberts K, Gabardi S, Fuhlbrigge AL, Camp PC, Goldberg HJ, Marty FM, Baden LR. Cytomegalovirus disease in lung transplantation: impact of recipient seropositivity and duration of antiviral prophylaxis. Transpl Infect Dis. 2013 Apr; 15(2):163-70. PMID: 23230972.
    Citations: 7     Fields:    Translation:Humans
  44. Lee RA, Gabardi S. Current trends in immunosuppressive therapies for renal transplant recipients. Am J Health Syst Pharm. 2012 Nov 15; 69(22):1961-75. PMID: 23135563.
    Citations: 22     Fields:    Translation:Humans
  45. Gabardi S, Olyaei A. Evaluation of potential interactions between mycophenolic acid derivatives and proton pump inhibitors. Ann Pharmacother. 2012 Jul-Aug; 46(7-8):1054-64. PMID: 22811345.
    Citations: 4     Fields:    Translation:Humans
  46. Riella LV, Gabardi S, Chandraker A. Dyslipidemia and its therapeutic challenges in renal transplantation. Am J Transplant. 2012 Aug; 12(8):1975-82. PMID: 22578270.
    Citations: 17     Fields:    Translation:Humans
  47. Gabardi S, Millen P, Hurwitz S, Martin S, Roberts K, Chandraker A. Atovaquone versus trimethoprim-sulfamethoxazole as Pneumocystis jirovecii pneumonia prophylaxis following renal transplantation. Clin Transplant. 2012 May-Jun; 26(3):E184-90. PMID: 22487221.
    Citations: 11     Fields:    Translation:HumansAnimalsCTClinical Trials
  48. Martin ST, Torabi MJ, Gabardi S. Influenza in solid organ transplant recipients. Ann Pharmacother. 2012 Feb; 46(2):255-64. PMID: 22234989.
    Citations: 4     Fields:    Translation:HumansCells
  49. Trofe-Clark J, Gabardi S, McDevitt-Potter L, Alloway RR. Immunosuppression, generic drugs and the FDA. Am J Transplant. 2012 Mar; 12(3):792-3; author reply 794. PMID: 22176626.
    Citations: 3     Fields:    Translation:Humans
  50. Ensor CR, Trofe-Clark J, Gabardi S, McDevitt-Potter LM, Shullo MA. Generic maintenance immunosuppression in solid organ transplant recipients. Pharmacotherapy. 2011 Nov; 31(11):1111-29. PMID: 22026398.
    Citations: 16     Fields:    Translation:Humans
  51. Gabardi S, Halloran PF, Friedewald J. An update on risk evaluation and mitigation strategies in transplantation. Am J Transplant. 2012 Jan; 12(1):257-8. PMID: 22026591.
    Citations: 1     Fields:    Translation:Humans
  52. McDevitt-Potter LM, Sadaka B, Tichy EM, Rogers CC, Gabardi S. A multicenter experience with generic tacrolimus conversion. Transplantation. 2011 Sep 27; 92(6):653-7. PMID: 21788920.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  53. Gabardi S, Halloran PF, Friedewald J. Managing risk in developing transplant immunosuppressive agents: the new regulatory environment. Am J Transplant. 2011 Sep; 11(9):1803-9. PMID: 21827622.
    Citations: 1     Fields:    
  54. Gabardi S, Catella J, Martin ST, Perrone R, Chandraker A, Magee CC, McDevitt-Potter LM. Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients. Ann Pharmacother. 2011 Sep; 45(9):e48. PMID: 21811001.
    Citations: 1     Fields:    Translation:Humans
  55. Gabardi S. Understanding risk evaluation and mitigation strategies in organ transplantation. Pharmacotherapy. 2011 Jul; 31(7):714-22. PMID: 21923459.
    Citations: 1     Fields:    Translation:Humans
  56. Alloway RR, Dupuis R, Gabardi S, Kaiser TE, Taber DJ, Tichy EM, Weimert-Pilch NA. Evolution of the role of the transplant pharmacist on the multidisciplinary transplant team. Am J Transplant. 2011 Aug; 11(8):1576-83. PMID: 21672154.
    Citations: 14     Fields:    Translation:Humans
  57. Martin ST, Roberts KL, Malek SK, Tullius SG, Vadivel N, De Serres S, Grafals M, Elsanjak A, Filkins BA, Chandraker A, Gabardi S. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal. Pharmacotherapy. 2011 Jun; 31(6):566-73. PMID: 21923440.
    Citations: 5     Fields:    Translation:HumansAnimals
  58. Martin ST, Tichy EM, Gabardi S. Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation. Pharmacotherapy. 2011 Apr; 31(4):394-407. PMID: 21449628.
    Citations: 8     Fields:    Translation:Humans
  59. Gabardi S, Carter D, Martin S, Roberts K. Recommendations for the proper use of nonprescription cough suppressants and expectorants in solid-organ transplant recipients. Prog Transplant. 2011 Mar; 21(1):6-13; quiz 14. PMID: 21485938.
    Citations: 1     Fields:    Translation:Humans
  60. Gabardi S, Martin ST, Roberts KL, Grafals M. Induction immunosuppressive therapies in renal transplantation. Am J Health Syst Pharm. 2011 Feb 01; 68(3):211-8. PMID: 21258026.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  61. Gabardi S, Baroletti SA. Comment: management of hypertension in renal transplant patients: a comprehensive review of nonpharmacologic and pharmacologic treatment strategies. Ann Pharmacother. 2010 Dec; 44(12):2040-1. PMID: 21119103.
    Citations:    Fields:    Translation:HumansAnimals
  62. Cutler C, Kesselheim A, Gabardi S, Andersson BS, Carpenter P, Khoury HJ, Litzow M, Rowley SD, Lanum S, Leather H, Tina Shih YC, Gale RP, Wingard JR, Appelbaum FR, Anasetti C. Generic immunosuppressants in hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011 Mar; 17(3):285-90. PMID: 21087678.
    Citations: 3     Fields:    Translation:Humans
  63. Gabardi S, Baroletti SA. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology. Pharmacotherapy. 2010 Oct; 30(10):1044-56. PMID: 20874042.
    Citations: 37     Fields:    Translation:HumansCells
  64. Gabardi S, Waikar SS, Martin S, Roberts K, Chen J, Borgi L, Sheashaa H, Dyer C, Malek SK, Tullius SG, Vadivel N, Grafals M, Abdi R, Najafian N, Milford E, Chandraker A. Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation. Clin J Am Soc Nephrol. 2010 Jul; 5(7):1298-304. PMID: 20507960.
    Citations: 26     Fields:    Translation:HumansCells
  65. Gabardi S, Olyaei A. Solid Organ Transplantation. Pharmacotherapy Principles & Practice. Chisholm MA, Schwinghammer TL, Wells BG, et al., eds. 2010.
  66. Gabardi S, Martin S, Sheashaa H, Borgi, L, Dyer C, Grafals M, Roberts K, Malek S, Tullius S, Chandraker A. Evaluation of fluorquinolones for the prevention of BK viremia in renal transplant recipients. Clinical Journal of the American Society of Nephrology. 2010; in print.
  67. Erickson AL, Roberts K, Malek SK, Chandraker AK, Tullius SG, Gabardi S. Analysis of infusion-site reactions in renal transplant recipients receiving peripherally administered rabbit antithymocyte globulin as compared with basiliximab. Transpl Int. 2010 Jun; 23(6):636-40. PMID: 20074083.
    Citations: 2     Fields:    Translation:HumansAnimals
  68. Erickson A, Malek S, Tullius S, Roberts K, Gabardi S. Analysis of infusion-site reactions in renal transplant recipients receiving peripherally administered antithymocyte globulin rabbit compared to basiliximab. Transplant International. 2010; ePub.
  69. Martin S, Gabardi S. . Medication adherence in solid organ transplant recipients and the impact of clinical pharmacy services. Journal of Pharmacy Practice and Research. 2009; 39(4):257-8.
  70. Gabardi S, Martin S, Sheashaa H, Borgi, L, Dyer C, Grafals M, Roberts K, Malek S, Tullius S, Chandraker A. . Evaluation of fluorquinolones for the prevention of BK viremia in renal transplant recipients. American Journal of Transplantation. 2009.
  71. Gabardi S, Degrado J, Mui E, Compton J, Roberts K, Malek S, Chandraker A, Tullius S. . Evaluation of early corticosteroid cessation versus long-term, low-dose corticosteroid therapy in expanded criteria donor renal transplant recipients. American Journal of Transplantation. 2009.
  72. Gabardi S, Martin S, Filkins B, Roberts K, Malek S, Tullius S, Chandraker A. . Induction therapy with rabbit antithymocyte globulin versus basiliximab and early steroid withdrawal in renal transplantation. American Journal of Transplantation. 2009.
  73. Erickson A, Malek S, Tullius S, Roberts K, Gabardi S. . Analysis of infusion-site reactions in renal transplant recipients receiving peripherally administered antithymocyte globulin rabbit compared to basiliximab. American Journal of Transplantation. 2009.
  74. Gabardi S. Drug dosing in acute kidney injury versus chronic renal insufficiency. Journal of Pharmacy Practice and Research. 2008; 38(3):175-6.
  75. Gabardi S, Olyaei A. Solid Organ Transplantation. Pharmacotherapy Principles & Practice. Chisholm MA, Schwinghammer TL, Wells BG, et al., eds. 2007; 829-52.
  76. Gabardi S, Kubiak DW, Chandraker AK, Tullius SG. Invasive fungal infections and antifungal therapies in solid organ transplant recipients. Transpl Int. 2007 Dec; 20(12):993-1015. PMID: 17617181.
    Citations: 12     Fields:    Translation:Humans
  77. Gabardi S, Munz K, Ulbricht C. A review of dietary supplement-induced renal dysfunction. Clin J Am Soc Nephrol. 2007 Jul; 2(4):757-65. PMID: 17699493.
    Citations: 20     Fields:    Translation:Humans
  78. Gabardi S, Kubiak D, Chandraker A, Tullius S. Invasive fungal infections and antifungal therapies in solid organ transplantation. Transplant International. 2007; 20(12):993-1015.
  79. Gabardi S, Baroletti S, McDevitt L, Saxer S, Rogers C. . Pharmaceutical Care. A Clinician’s Guide to Donation and Transplantation. LaPointe-Rudow D, Ohler L, Shafer T, eds. 2007; 613-50.
  80. Gabardi S. Alternative Viewpoints: “Factors Influencing the Magnitude and Clinical Significance of Drug Interactions between Azole Antifungals and Select Immunosuppressants”. Pharmacotherapy. 2007; 27(4):e3-e6.
  81. Gabardi S, Munz K, Ulbricht C. A Review of Dietary Supplement–Induced Renal Dysfunction. Clinical Journal of the American Society of Nephrology. 2007; 2(4):757-65.
  82. Gabardi S, McDevitt L. Efficacy and safety of CMV prophylaxis with valganciclovir 900 mg/day for 100 days versus 450 mg/day for 6 months post-renal transplantation. American Journal of Transplantation. 2006.
  83. Gabardi S. Drug use evaluation of caspofungin at an urban, academic medical center. American Journal of Health-System Pharmacists. 2005.
  84. Gabardi S, Abramson S. Drug dosing in chronic kidney disease. Med Clin North Am. 2005 May; 89(3):649-87. PMID: 15755472.
    Citations: 19     Fields:    Translation:Humans
  85. Gabardi S. Bitter Melon. Natural Standard Herb and Supplement Reference: Evidence-Based Clinical Reviews. 2005; 76-80.
  86. Gabardi S, Abramson S. Drug-dosing in chronic kidney disease. Medical Clinics of North America. 2005; 89(3):649-87.
  87. Gabardi S, Fiumara K, Lowry C, Fanikos J. Drug utilization evaluation of liposomal amphotericin B at an urban, academic medical center, with an evaluation of six years of clinical experience. American Journal of Health-System Pharmacists. 2004.
  88. Gabardi S, Magee CC, Baroletti SA, Powelson JA, Cina JL, Chandraker AK. Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis. Pharmacotherapy. 2004 Oct; 24(10):1323-30. PMID: 15628830.
    Citations: 9     Fields:    Translation:Humans
  89. Gabardi S, Luu L. Nonprescription analgesics and their use in solid-organ transplantation: a review. Prog Transplant. 2004 Sep; 14(3):182-90. PMID: 15495777.
    Citations: 2     Fields:    Translation:Humans
  90. Baroletti S, Bencivenga GA, Gabardi S. Treating gout in kidney transplant recipients. Prog Transplant. 2004 Jun; 14(2):143-7. PMID: 15264458.
    Citations: 3     Fields:    Translation:Humans
  91. Gabardi S, Cerio J. Future immunosuppressive agents in solid-organ transplantation. Prog Transplant. 2004 Jun; 14(2):148-56. PMID: 15264459.
    Citations: 2     Fields:    Translation:Humans
  92. Winkelmayer WC, Kewalramani R, Rutstein M, Gabardi S, Vonvisger T, Chandraker A. Pharmacoepidemiology of anemia in kidney transplant recipients. J Am Soc Nephrol. 2004 May; 15(5):1347-52. PMID: 15100376.
    Citations: 15     Fields:    Translation:Humans
  93. Talon D, Vedel G, Gabardi S, Conort O. . Evaluation of a 14-month period of glycopeptide use during a period of restricted glycopeptide prescribing. European Journal of Hospital Pharmacists. 2004; 10(2):31-5.
  94. Gabardi S, Luu L. A review of nonprescription analgesics, with a focus on their use in solid-organ transplantation. Progress in Transplantation. 2004; 14(3):183-90.
  95. Gabardi S, Tran JL, Clarkson MR. Enteric-coated mycophenolate sodium. Ann Pharmacother. 2003 Nov; 37(11):1685-93. PMID: 14565799.
    Citations: 5     Fields:    Translation:Humans
  96. Baroletti SA, Gabardi S, Magee CC, Milford EL. Calcium channel blockers as the treatment of choice for hypertension in renal transplant recipients: fact or fiction. Pharmacotherapy. 2003 Jun; 23(6):788-801. PMID: 12820820.
    Citations: 6     Fields:    Translation:Humans
  97. Basch E, Gabardi S, Ulbricht C. Bitter melon (Momordica charantia): a review of efficacy and safety. Am J Health Syst Pharm. 2003 Feb 15; 60(4):356-9. PMID: 12625217.
    Citations: 64     Fields:    Translation:HumansAnimals
  98. Kewalramani R, Winkelmayer WC, Rutstein M, Gabardi S, Greenfield J, VonVisger TT, Singh AK, Chandraker A. . Anemia in renal transplant recipients: an emerging concern. American Journal of Transplantation. 2003; 3(Supplement 5):320.
  99. Baroletti S, Gabardi S, Magee C, Milford E. A review of calcium channel antagonists as drug of choice for hypertension in the renal transplant population. Pharmacotherapy. 2003; 23(6):788-801.
  100. Gabardi S, Powelson J, Baroletti SA, Cina JL, Goggins WC. . Efficacy and safety of valganciclovir in prophylaxis of cytomegalovirus disease in renal transplant recipients. Pharmacotherapy. 2003; 23(3):412-3.
  101. Basch EM, Gabardi S, Ulbricht CE. Bitter Melon (Momordica charantia): A review of efficacy and safety. American Journal of Health-System Pharmacy. 2003; 60(4):356-9.
  102. Conort O, Gabardi S, Didier MP, Hazebroucq G, Cariou A. Intravenous to oral conversion of fluoroquinolones: knowledge versus clinical practice patterns. Pharm World Sci. 2002 Apr; 24(2):67-70. PMID: 12061136.
    Citations: 3     Fields:    Translation:Humans
  103. Gabardi S. . Bitter melon: a systematic review. In: Basch, EM, Ulbricht CE, Bent S, Boon H, Smith M, eds. Natural Standard Evidence-Based Clinical Guide. Available online at www.naturalstandard.com. 2001.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Gabardi's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (268)
Explore
_
Co-Authors (42)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
© 2023 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.